Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2020

Open Access 01-12-2020 | Stroke | Original investigation

Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study

Authors: Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, Jun Hyeok Lee, Dae Ryong Kang, Ki Chul Sung, Jang Young Kim, Ji Hye Huh

Published in: Cardiovascular Diabetology | Issue 1/2020

Login to get access

Abstract

Background

Despite the known association between non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD), whether NAFLD predicts future CVD events, especially CVD mortality, remains uncertain. We evaluated the relationship between fatty liver index (FLI), a validated marker of NAFLD, and risk of major adverse cardiac events (MACEs) in a large population-based study.

Methods

We identified 3011,588 subjects in the Korean National Health Insurance System cohort without a history of CVD who underwent health examinations from 2009 to 2011. The primary endpoint was a composite of cardiovascular deaths, non-fatal myocardial infarction (MI), and ischemic stroke. A Cox proportional hazards regression analysis was performed to assess association between the FLI and the primary endpoint.

Results

During the median follow-up period of 6 years, there were 46,010 cases of MACEs (7148 cases of cardiovascular death, 16,574 of non-fatal MI, and 22,288 of ischemic stroke). There was a linear association between higher FLI values and higher incidence of the primary endpoint. In the multivariable models adjusted for factors, such as body weight and cholesterol levels, the hazard ratio for the primary endpoint comparing the highest vs. lowest quartiles of the FLI was 1.99 (95% confidence interval [CIs], 1.91–2.07). The corresponding hazard ratios (95% CIs) for cardiovascular death, non-fetal MI, and ischemic stroke were 1.98 (1.9–2.06), 2.16 (2.01–2.31), and 2.01 (1.90–2.13), respectively (p < 0.001). The results were similar when we performed stratified analyses by age, sex, use of dyslipidemia medication, obesity, diabetes, and hypertension.

Conclusions

Our findings indicate that the FLI, which is a surrogate marker of NAFLD, has prognostic value for detecting individuals at higher risk for cardiovascular events.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, Cortez-Pinto H, Grieco A, Machado MV, Miele L, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Digest Liver Dis. 2015;47(12):997–1006.CrossRef Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, Cortez-Pinto H, Grieco A, Machado MV, Miele L, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Digest Liver Dis. 2015;47(12):997–1006.CrossRef
2.
go back to reference Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, Rhee EJ. Nonalcoholic fatty liver disease in diabetes. Part I: epidemiology and diagnosis. Diabetes Metab J. 2019;43(1):31–45.CrossRef Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, Rhee EJ. Nonalcoholic fatty liver disease in diabetes. Part I: epidemiology and diagnosis. Diabetes Metab J. 2019;43(1):31–45.CrossRef
3.
go back to reference Lonardo A, Sookoian S, Pirola CJ, Targher G. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism. 2016;65(8):1136–50.CrossRef Lonardo A, Sookoian S, Pirola CJ, Targher G. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism. 2016;65(8):1136–50.CrossRef
4.
go back to reference Huh JH, Ahn SV, Koh SB, Choi E, Kim JY, Sung KC, Kim EJ, Park JB. A prospective study of fatty liver index and incident hypertension: the KoGES-ARIRANG study. Plos One. 2015;10(11):e0143560.CrossRef Huh JH, Ahn SV, Koh SB, Choi E, Kim JY, Sung KC, Kim EJ, Park JB. A prospective study of fatty liver index and incident hypertension: the KoGES-ARIRANG study. Plos One. 2015;10(11):e0143560.CrossRef
5.
go back to reference Yadav D, Choi E, Ahn SV, Koh SB, Sung KC, Kim JY, Huh JH. Fatty liver index as a simple predictor of incident diabetes from the KoGES-ARIRANG study. Medicine. 2016;95(31):e4447.CrossRef Yadav D, Choi E, Ahn SV, Koh SB, Sung KC, Kim JY, Huh JH. Fatty liver index as a simple predictor of incident diabetes from the KoGES-ARIRANG study. Medicine. 2016;95(31):e4447.CrossRef
6.
go back to reference Ferrell JM, Chiang JYL. Understanding bile acid signaling in diabetes: from pathophysiology to therapeutic targets. Diabetes Metab J. 2019;43(3):257–72.CrossRef Ferrell JM, Chiang JYL. Understanding bile acid signaling in diabetes: from pathophysiology to therapeutic targets. Diabetes Metab J. 2019;43(3):257–72.CrossRef
7.
go back to reference Huh JH, Kim JY, Choi E, Kim JS, Chang Y, Sung KC. The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study. Plos One. 2017;12(7):e0180951.CrossRef Huh JH, Kim JY, Choi E, Kim JS, Chang Y, Sung KC. The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study. Plos One. 2017;12(7):e0180951.CrossRef
8.
go back to reference Kim KS, Lee BW, Kim YJ, Lee DH, Cha BS, Park CY. Nonalcoholic fatty liver disease and diabetes: part II: treatment. Diabetes Metab J. 2019;43(2):127–43.CrossRef Kim KS, Lee BW, Kim YJ, Lee DH, Cha BS, Park CY. Nonalcoholic fatty liver disease and diabetes: part II: treatment. Diabetes Metab J. 2019;43(2):127–43.CrossRef
9.
go back to reference Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association (vol 107, pg 811, 2012). Am J Gastroenterol. 2012;107(10):1598.CrossRef Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association (vol 107, pg 811, 2012). Am J Gastroenterol. 2012;107(10):1598.CrossRef
10.
go back to reference Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V, Grp LS. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharm Ther. 2014;40(10):1209–22.CrossRef Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V, Grp LS. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharm Ther. 2014;40(10):1209–22.CrossRef
11.
go back to reference Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. Bmc Gastroenterol. 2006;6:33.CrossRef Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. Bmc Gastroenterol. 2006;6:33.CrossRef
12.
go back to reference Kahl S, Strassburger K, Nowotny B, Livingstone R, Kluppelholz B, Kessel K, Hwang JH, Giani G, Hoffmann B, Pacini G, et al. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS ONE. 2014;9(4):e94059.CrossRef Kahl S, Strassburger K, Nowotny B, Livingstone R, Kluppelholz B, Kessel K, Hwang JH, Giani G, Hoffmann B, Pacini G, et al. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS ONE. 2014;9(4):e94059.CrossRef
13.
go back to reference Sviklane L, Olmane E, Dzerve Z, Kupcs K, Pirags V, Sokolovska J. Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. J Gastroenterol Hepatol. 2018;33(1):270–6.CrossRef Sviklane L, Olmane E, Dzerve Z, Kupcs K, Pirags V, Sokolovska J. Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. J Gastroenterol Hepatol. 2018;33(1):270–6.CrossRef
14.
go back to reference Pais R, Giral P, Khan JF, Rosenbaum D, Housset C, Poynard T, Ratziu V, Grp LS. Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol. 2016;65(1):95–102.CrossRef Pais R, Giral P, Khan JF, Rosenbaum D, Housset C, Poynard T, Ratziu V, Grp LS. Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol. 2016;65(1):95–102.CrossRef
15.
go back to reference Pais R, Redheuil A, Cluzel P, Ratziu V, Giral P. Relationship among fatty liver, specific and multiple-site atherosclerosis, and 10-year framingham score. Hepatology. 2019;69(4):1453–63.CrossRef Pais R, Redheuil A, Cluzel P, Ratziu V, Giral P. Relationship among fatty liver, specific and multiple-site atherosclerosis, and 10-year framingham score. Hepatology. 2019;69(4):1453–63.CrossRef
16.
go back to reference Seong SC, Kim YY, Park SK, Khang YH, Kim HC, Park JH, Kang HJ, Do CH, Song JS, Lee EJ, et al. Cohort profile: the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS) in Korea. Bmj Open. 2017;7(9):e016640.CrossRef Seong SC, Kim YY, Park SK, Khang YH, Kim HC, Park JH, Kang HJ, Do CH, Song JS, Lee EJ, et al. Cohort profile: the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS) in Korea. Bmj Open. 2017;7(9):e016640.CrossRef
17.
go back to reference Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36(27):4391–400.CrossRef Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36(27):4391–400.CrossRef
18.
go back to reference Tuttolomondo A, Petta S, Casuccio A, Maida C, Corte VD, Daidone M, Di Raimondo D, Pecoraro R, Fonte R, Cirrincione A, et al. Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. Cardiovasc Diabetol. 2018;17(1):28.CrossRef Tuttolomondo A, Petta S, Casuccio A, Maida C, Corte VD, Daidone M, Di Raimondo D, Pecoraro R, Fonte R, Cirrincione A, et al. Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. Cardiovasc Diabetol. 2018;17(1):28.CrossRef
19.
go back to reference Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600.CrossRef Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600.CrossRef
20.
go back to reference Lerchbaum E, Pilz S, Grammer TB, Boehm BO, Stojakovic T, Obermayer-Pietsch B, Marz W. The fatty liver index is associated with increased mortality in subjects referred to coronary angiography. Nutr Metab Cardiovas. 2013;23(12):1231–8.CrossRef Lerchbaum E, Pilz S, Grammer TB, Boehm BO, Stojakovic T, Obermayer-Pietsch B, Marz W. The fatty liver index is associated with increased mortality in subjects referred to coronary angiography. Nutr Metab Cardiovas. 2013;23(12):1231–8.CrossRef
21.
go back to reference Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–8.CrossRef Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–8.CrossRef
22.
go back to reference Schlett CL, Lorbeer R, Arndt C, Auweter S, Machann J, Hetterich H, Linkohr B, Rathmann W, Peters A, Bamberg F. Association between abdominal adiposity and subclinical measures of left-ventricular remodeling in diabetics, prediabetics and normal controls without history of cardiovascular disease as measured by magnetic resonance imaging: results from the KORA-FF4 Study. Cardiovasc Diabetol. 2018;17(1):88.CrossRef Schlett CL, Lorbeer R, Arndt C, Auweter S, Machann J, Hetterich H, Linkohr B, Rathmann W, Peters A, Bamberg F. Association between abdominal adiposity and subclinical measures of left-ventricular remodeling in diabetics, prediabetics and normal controls without history of cardiovascular disease as measured by magnetic resonance imaging: results from the KORA-FF4 Study. Cardiovasc Diabetol. 2018;17(1):88.CrossRef
23.
go back to reference Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51(2):595–602.CrossRef Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51(2):595–602.CrossRef
24.
go back to reference Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–54.CrossRef Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–54.CrossRef
25.
go back to reference Wang S, Zhang J, Zhang W, Wang H, Hou J, Zhang R, Liu H, Wu S. Predictive value of body mass index combined with waist circumference for new-onset nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Nan Fang Yi Ke Da Xue Xue Bao. 2019;39(11):1293–7.PubMed Wang S, Zhang J, Zhang W, Wang H, Hou J, Zhang R, Liu H, Wu S. Predictive value of body mass index combined with waist circumference for new-onset nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Nan Fang Yi Ke Da Xue Xue Bao. 2019;39(11):1293–7.PubMed
26.
go back to reference Hwang YC, Ahn HY, Park SW, Park CY. Nonalcoholic fatty liver disease associates with increased overall mortality and death from cancer, cardiovascular disease, and liver disease in women but not men. Clin Gastroenterol H. 2018;16(7):1131.CrossRef Hwang YC, Ahn HY, Park SW, Park CY. Nonalcoholic fatty liver disease associates with increased overall mortality and death from cancer, cardiovascular disease, and liver disease in women but not men. Clin Gastroenterol H. 2018;16(7):1131.CrossRef
27.
go back to reference Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L, Perseghin G. Fatty liver index and mortality: the cremona study in the 15th year of follow-up. Hepatology. 2011;54(1):145–52.CrossRef Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L, Perseghin G. Fatty liver index and mortality: the cremona study in the 15th year of follow-up. Hepatology. 2011;54(1):145–52.CrossRef
28.
go back to reference Khang AR, Lee HW, Yi D, Kang YH, Son SM. The fatty liver index, a simple and useful predictor of metabolic syndrome: analysis of the Korea National Health and Nutrition Examination Survey 2010–2011. Diabetes Metab Syndr Obes. 2019;12:181–90.CrossRef Khang AR, Lee HW, Yi D, Kang YH, Son SM. The fatty liver index, a simple and useful predictor of metabolic syndrome: analysis of the Korea National Health and Nutrition Examination Survey 2010–2011. Diabetes Metab Syndr Obes. 2019;12:181–90.CrossRef
29.
go back to reference Kaul U, Parmar D, Manjunath K, Shah M, Parmar K, Patil KP, Jaiswal A. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovasc Diabetol. 2019;18(1):80.CrossRef Kaul U, Parmar D, Manjunath K, Shah M, Parmar K, Patil KP, Jaiswal A. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovasc Diabetol. 2019;18(1):80.CrossRef
30.
go back to reference Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–53.CrossRef Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–53.CrossRef
31.
go back to reference Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol. 2016;65(2):425–43.CrossRef Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol. 2016;65(2):425–43.CrossRef
32.
go back to reference Olubamwo OO, Virtanen JK, Pihlajamaki J, Mantyselka P, Tuomainen TP. Fatty liver index as a predictor of increased risk of cardiometabolic disease: finding from the Kuopio ischaemic heart disease risk factor study cohort. BMJ Open. 2019;9:e031420.CrossRef Olubamwo OO, Virtanen JK, Pihlajamaki J, Mantyselka P, Tuomainen TP. Fatty liver index as a predictor of increased risk of cardiometabolic disease: finding from the Kuopio ischaemic heart disease risk factor study cohort. BMJ Open. 2019;9:e031420.CrossRef
Metadata
Title
Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
Authors
Jun Hyung Kim
Jin Sil Moon
Seok Joon Byun
Jun Hyeok Lee
Dae Ryong Kang
Ki Chul Sung
Jang Young Kim
Ji Hye Huh
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2020
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-020-01025-4

Other articles of this Issue 1/2020

Cardiovascular Diabetology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.